European Journal of Internal Medicine
Volume 20, Supplement 2 , Pages S309-S318, July 2009

Efficacy and Safety of Incretin-Based Therapies in Patients with Type 2 Diabetes Mellitus✩

  • Matthew P. Gilbert, DO, MPH
    • ,
  • Richard E. Pratley, MD

      Affiliations

    • Corresponding Author InformationCorresponding author. Requests for reprints should be addressed to Richard E. Pratley, MD, Diabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine, Given C33189, Beaumont Avenue, Burlington, Vermont 05405.

Diabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine, Burlington, Vermont, USA

published online 22 June 2009.

Abstract 

This article aims to provide an overview of efficacy and safety data on glucagon-like peptide–1 (GLP-1) receptor agonists and dipeptidyl peptidase–4 (DPP-4) inhibitors in the treatment of type 2 diabetes mellitus. Our goal is to differentiate the clinical profiles of GLP-1 receptor agonists and DPP-4 inhibitors, as well as the individual agents within each class. Additionally, we examine the utility of GLP-1 receptor agonists and DPP-4 inhibitors as these agents may be applied at different stages of type 2 diabetes therapy and discuss recently published clinical findings and their implications for treatment.

Keywords: DPP-4, exenatide-LAR, GLP-1 receptor agonist, liraglutide, sitagliptin

 

✩ This article is a copublication with The American Journal of Medicine, 122, S11-S24. For citation purposes please use European Journal of Internal Medicine, 20, S309-S318.

PII: S0953-6205(09)00096-X

doi:10.1016/j.ejim.2009.05.011

European Journal of Internal Medicine
Volume 20, Supplement 2 , Pages S309-S318, July 2009

Article Tools

* Image Usage & Resolution